BOBAK “BOBBY” AZAMIAN
CO-FOUNDER, CHAIRMAN, CEO, TARSUS PHARMACEUTICALS
WHY: Co-founded Irvine-based development-stage drugmaker with a focus on eye care. Went public in 2020 at $16 share; now trades at more than $43 with $1.6B market cap.
IN THE NEWS: Reported 65% jump to $40.8M in second-quarter sales for its Xdemvy eyedrop, the first and only FDA-approved treatment for ocular disease Demodex blepharitis.
NOTABLE: Co-founded and led two other therapeutics companies—Vibrato Medical, focused on wearable treatments for peripheral arterial diseases, and Metavention, focused on interventional treatments for metabolic diseases—and led both through multiple financings.
QUOTABLE: “The Xdemvy launch continues building a strong foundation to serve patients and doctors with a high-value, new category of medicine, with impressive quarter-over-quarter growth and robust payer coverage, including additional Medicare coverage—making it one of the most successful eyecare launches to date.”
